Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 14.2% in September

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 195,600 shares, a decrease of 14.2% from the August 31st total of 228,000 shares. Based on an average trading volume of 162,200 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.8% of the company’s shares are sold short.

Institutional Investors Weigh In On Bolt Biotherapeutics

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. Acuitas Investments LLC grew its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 21.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 630,507 shares of the company’s stock after purchasing an additional 112,555 shares during the quarter. Acuitas Investments LLC owned approximately 1.65% of Bolt Biotherapeutics worth $473,000 at the end of the most recent reporting period. 86.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Thursday, August 15th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Bolt Biotherapeutics currently has an average rating of “Hold” and an average target price of $3.50.

Bolt Biotherapeutics Stock Up 6.3 %

BOLT traded up $0.04 during trading hours on Friday, hitting $0.62. 244,673 shares of the company’s stock were exchanged, compared to its average volume of 175,730. The firm has a market cap of $23.65 million, a P/E ratio of -0.37 and a beta of 0.93. Bolt Biotherapeutics has a 12-month low of $0.55 and a 12-month high of $1.56. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average of $0.68 and a 200 day moving average of $0.87.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.08). The company had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $1.19 million. Bolt Biotherapeutics had a negative return on equity of 61.40% and a negative net margin of 592.57%. Analysts predict that Bolt Biotherapeutics will post -1.44 EPS for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.